Mammalian target of rapamycin (mTOR) inhibitors can achieve satisfactory results in treating TSC, which has been recommended as a first‐line treatment option in NCCN guidelines5 The efficacy of mTOR inhibitor everolimus in AML was broadly investigated in recent studies with a reduced the AML volume by ≥50% in more than 50% patients with TSC and a ≥25% reduction in tumor volume in 71.4% patients in non‐TSC AML at 6 months of administration.6, 7. This evidence concerns the gene TSC1 and acute myeloid leukemia.